Moreover, in a phase I clinical trial in patients with non-small-cell lung cancer conducted to evaluate the safety of a DC vaccine pulsed with survivin mucin 1, cell surface associated (MUC1), silenced with suppressor of cytokine signaling 1 (SOCS1), and flagellin used as an adjuvant, the results showed that the vaccine is well tolerated and improves patients’ quality of life [180]. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.